OncoMatch/Clinical Trials/NCT05927571
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Is NCT05927571 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Cevostamab and Elranatamab for relapsed or refractory multiple myeloma.
Treatment: Cevostamab · Elranatamab · Tocilizumab — The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: FcRH5-targeted therapy (cevostamab)
Prior treatment with cevostamab or another agent targeting fragment crystallizable receptor-like 5 (FcRH5)
Cannot have received: elranatamab (elranatamab)
Prior treatment with elranatamab
Cannot have received: allogeneic stem cell transplant
Prior allogeneic stem cell transplantation (SCT)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05927571 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior FcRH5-targeted therapy, elranatamab, allogeneic stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages